Edition:
United Kingdom

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

69.18USD
18 Jan 2019
Change (% chg)

$0.53 (+0.77%)
Prev Close
$68.65
Open
$69.23
Day's High
$69.58
Day's Low
$68.52
Volume
3,118,675
Avg. Vol
2,713,974
52-wk High
$89.53
52-wk Low
$60.32

Select another date:

Mon, Jan 7 2019

Photo

Merck loses bid to revive $200 million Gilead verdict at U.S. high court

WASHINGTON The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million (£156.5 million) verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs.

Merck loses bid to revive $200 million Gilead verdict at U.S. high court

WASHINGTON The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs.

UPDATE 2-Merck loses bid to revive $200 mln Gilead verdict at U.S. high court

WASHINGTON, Jan 7 The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs.

Merck loses bid to revive $200 mln Gilead verdict at U.S. high court

WASHINGTON, Jan 7 The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs.

Agenus shares soar after cancer therapy deal with Gilead

Shares of Agenus Inc surged as much as 70 percent on Thursday after the company said it would develop and market up to five of its immuno-oncology therapies in partnership with Gilead Sciences Inc.

UPDATE 1-Agenus shares soar after cancer therapy deal with Gilead

Dec 20 Shares of Agenus Inc surged as much as 70 percent on Thursday after the company said it would develop and market up to five of its immuno-oncology therapies in partnership with Gilead Sciences Inc.

Gilead, Agenus sign deal to develop immuno-oncology therapies

Dec 20 Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies.

Gilead Sciences snares Roche veteran O'Day as CEO

Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum.

Gilead Sciences snares Roche veteran O'Day as CEO

Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum.

UPDATE 4-Gilead Sciences snares Roche veteran O'Day as CEO

* William Anderson to replace O'Day as Roche Pharmaceuticals CEO

Select another date: